In India, Eli Lilly launched an anti-diabetes drug that can be injected once a week.
The Indian diabetes market is huge and it is likely to grow exponentially.
Eli Lilly has recently been rated ‘outperform’.
Just a couple of weeks ago, Eli Lilly (NYSE:LLY) launched its anti-diabetes drug Trulicity (dulaglutide) in India, a country witnessing epic proportions of diabetic patients in its hospitals. Trulicity is a once-a-week non-insulin drug that is recommended for type 2 diabetes. click here to read more.